Extended Data Fig. 11: PTEN loss sensitizes tumors to enhancement of anti-tumor immune response by pharmacological PI3Kβ-specific inhibition.
From: PI3Kβ controls immune evasion in PTEN-deficient breast tumours
a, Western blot analysis of RCT-E302 mouse mammary tumor cells with deleted Pten (RCT-E302-sgPten) and parental RCT-E302 cells. b–c, Flow cytometry analysis of tumor cells and immune infiltrate from RCT-E302-sgPten (b) or RCT-E302 (c) tumors harvested from FVB mice treated with AZD6482 or a vehicle control (n = 10 tumors per group). d, Western blot analysis of BPP (Brca1/Trp53/Pten triple-null) and BP (Brca1/Trp53 double-null) mouse mammary tumor cells. e–f, Flow cytometry analysis of tumor cells and immune infiltrate from BPP (e) or BP (f) tumors harvested from FVB mice treated with AZD6482 or a vehicle control (n = 10 tumors per group). Apparent molecular weights in kDa are indicated for immunoblots. For comparison of two means (b–c and e–f), unpaired, two-tail t-test with Welch’s correction assuming unequal variance. Flow cytometry gating profiles available on Supplementary Fig. 8.
